Welcome to LookChem.com Sign In|Join Free

CAS

  • or

179545-77-8

Post Buying Request

179545-77-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

179545-77-8 Usage

Description

Tanomastat, also known as a non-peptidic inhibitor, is a white solid compound that exhibits potent inhibitory activity against matrix metalloproteinases (MMPs) such as MMP-2, MMP-3, and MMP-9. It has demonstrated the ability to inhibit angiogenesis, a process critical for tumor growth and metastasis. Tanomastat has been investigated in various animal models and has undergone a phase III clinical trial for its potential use in treating pancreatic, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and ovarian cancer patients.

Uses

Used in Pharmaceutical Industry:
Tanomastat is used as a Matrix Metalloproteinase inhibitor for its ability to inhibit the activity of MMP-2, MMP-3, and MMP-9, which are enzymes involved in the breakdown of extracellular matrix proteins. This inhibition can help prevent tumor metastasis and angiogenesis, making it a potential therapeutic agent for various types of cancer.
Used in Oncology:
Tanomastat is used as an angiogenesis inhibitor for its ability to prevent the formation of new blood vessels that supply nutrients to tumors, thereby limiting their growth and spread. This application makes it a valuable tool in the fight against cancer, particularly in the treatment of pancreatic, SCLC, NSCLC, and ovarian cancer.
Used in Drug Development:
Tanomastat is used as a research compound for the development of new drugs targeting MMPs and angiogenesis. Its potent inhibitory activity and demonstrated efficacy in animal models make it a promising candidate for further investigation and potential clinical use.
Chemical Properties:
Tanomastat is a white solid with an optical rotation of +82° (C 1.5 acetone), indicating its chiral nature and potential for further chemical modification and optimization.

Check Digit Verification of cas no

The CAS Registry Mumber 179545-77-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,5,4 and 5 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 179545-77:
(8*1)+(7*7)+(6*9)+(5*5)+(4*4)+(3*5)+(2*7)+(1*7)=188
188 % 10 = 8
So 179545-77-8 is a valid CAS Registry Number.
InChI:InChI=1/C23H19ClO3S/c24-20-12-10-17(11-13-20)16-6-8-18(9-7-16)22(25)14-19(23(26)27)15-28-21-4-2-1-3-5-21/h1-13,19H,14-15H2,(H,26,27)/t19-/m1/s1

179545-77-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name Tanomastat

1.2 Other means of identification

Product number -
Other names BAY12-9566,(S)-4Chloro-g-oxo-a-[(phenylthio)methyl][1,1biphenyl]-4-butanoicAcid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:179545-77-8 SDS

179545-77-8Upstream product

179545-77-8Downstream Products

179545-77-8Relevant articles and documents

Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors

-

, (2008/06/13)

Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have the generalized formula (T)xA—B—D—E—G wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group; x is 0, 1, or 2; the group D represents the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and the group G represents and with the proviso that when G is each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 179545-77-8